Document:

EX-10.13

 Exhibit 10.13 

G1 THERAPEUTICS, INC. 
 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY 
 The Board of Directors of G1 Therapeutics, Inc. (the
“Company”) has approved the following Non-Employee Director Compensation Policy (this “Policy”) which establishes compensation to be paid to
non-employee directors of the Company, effective upon the completion of the Company’s initial public offering (“Effective Time”), to provide an inducement to obtain and retain the
services of qualified persons to serve as members of the Company’s Board of Directors. 
 Applicable Persons 

This Policy shall apply to each director of the Company who is not an employee of the Company or any Affiliate (each, a “Non-Employee Director”). “Affiliate” shall mean an entity which is a direct or indirect parent or subsidiary of the Company, as determined pursuant to Section 424 of the Internal
Revenue Code of 1986, as amended. 
 Stock Option Grants 

All stock option amounts set forth herein shall be subject to automatic adjustment in the event of any stock split or other recapitalization
affecting the Company’s common stock. 
 Annual Stock Option Grants 

Annually, each Non-Employee Director shall be granted a
non-qualified stock option to purchase the number of shares of the Company’s common stock equal to 0.037% of the Company’s outstanding common stock under the Company’s 2017 Employee, Director
and Consultant Equity Incentive Plan (the “Stock Plan”) on the date of the first meeting of the Board of Directors held following the Company’s annual meeting of stockholders. 

Initial Stock Option Grant For Newly Appointed or Elected Directors 

Each new Non-Employee Director shall be granted a non-qualified
stock option to purchase the number of shares of the Company’s common stock equal to 0.073% of the Company’s outstanding common stock under the Stock Plan at the first regularly scheduled meeting of the Board of Directors on or after his
or her initial appointment or election to the Board of Directors. 
 Terms for All Option Grants 

Unless otherwise specified by the Board of Directors or the Compensation Committee at the time of grant, all options granted under this Policy
shall (i) have an exercise price equal to the fair market value of the Company’s common stock as determined in the Stock Plan on the grant date; (ii) terminate ten years after the grant date and (iii) contain such other terms and
conditions as set forth in the form of option agreement approved by the Board of Directors or the Compensation Committee prior to the grant date. Subject to the continued service of each Non-Employee Director
and unless otherwise specified by the Board of Directors or the Compensation Committee at the time of grant, each annual stock option grant shall vest on the first anniversary of the date of grant and each initial stock option grant shall vest in
equal monthly installments following the date of grant until the third anniversary of the grant date. 

 Annual Fees 

Each Non-Employee Directors serving on the Board of Directors and the Audit Committee, Compensation
Committee and/or Nominating and Corporate Governance Committee, as applicable, shall be entitled to the following annual amounts (the “Annual Fees”): 
  

									
	 Board of Directors or
Committee of Board of
Directors
	  	Annual Retainer Amount for
Member	 	  	Annual Retainer Amount for
Chair	 
	 Board of Directors
	  	$	35,000	 	  	$	25,000	 
	 Audit Committee
	  	$	7,500	 	  	$	15,000	 
	 Compensation Committee
	  	$	5,000	 	  	$	10,000	 
	 Nominating and Corporate Governance Committee
	  	$	3,750	 	  	$	7,000	 

 Except as otherwise set forth in this Policy, all Annual Fees shall be paid for the period from January 1
through December 31 of each year. Such Annual Fees shall be paid in cash. 
 Payments 

Payments payable to Non-Employee Directors shall be paid quarterly in arrears promptly following the
end of each fiscal quarter, provided that (i) the amount of such payment shall be prorated for any portion of such quarter that such director was not serving on the Board or a committee and (ii) no fee shall be payable in respect of any
period prior to the date such director was elected to the Board or a committee. 
 Expenses 

Upon presentation of documentation of such expenses reasonably satisfactory to the Company, each
Non-Employee Director shall be reimbursed for his or her reasonable out-of-pocket business expenses incurred in connection with
attending meetings of the Board of Directors and committees thereof or in connection with other business related to the Board of Directors. 
 Amendments

 The Compensation Committee shall periodically review this Policy to assess whether any amendments in the type and amount of
compensation provided herein should be made and shall make recommendations to the Board of Directors for its approval of any amendments to this Policy. 

  
 2EX-10.14

 Exhibit 10.14 

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT 

THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is entered into as of May 5, 2017, by and between G1
Therapeutics, Inc., a Delaware corporation (the “Company”) and Jennifer Moses (the “Employee”). 
 WITNESSETH:

 WHEREAS, Employee and the Company entered into an Employment Agreement effective as of May 10, 2016, (the “Employment
Agreement”); 
 WHEREAS, Employee and the Company wish to alter certain terms of the Employment Agreement, particularly with respect to
Employee’s employment compensation, subject to and effective upon the completion of the Company’s initial public offering of its common stock (the “IPO”); and 

WHEREAS, in light of the foregoing, Employee and the Company desire to mutually and voluntarily amend the Employment Agreement pursuant to the
terms as set forth herein. 
 NOW, THEREFORE, in consideration of the foregoing, the mutual promises herein contained, and other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows. 

1. AMENDMENT TO SECTION 3(a) OF THE EMPLOYMENT AGREEMENT. Section 3(a) of the Employment Agreement is modified, subject to and
effective upon the completion of the IPO, by replacing the existing Section 3(a) in its entirety with a new Section 3(a) as follows: 
  

	 	a)	BASE SALARY. The Company will pay Employee a base salary (the “Base Salary”) at an annual rate of Two Hundred Thirty-Five Thousand Dollars ($235,000.00), payable in equal installments in accordance with
the Company’s customary payroll practices as in effect from time to time. The Base Salary may be reviewed from time to time by the Company and may be increased in the sole discretion of the Board. The Base Salary may also be decreased in
connection with any Company-wide decrease in executive compensation. 

 2. AMENDMENT TO SECTION 3(b) OF THE EMPLOYMENT
AGREEMENT. Section 3(b) of the Employment Agreement is modified, subject to and effective upon the completion of the IPO, by replacing the existing Section 3(b) in its entirety with a new Section 3(b) as follows: 

 

	 	b)	 ANNUAL BONUS. As long as Employee remains employed by the Company, Employee will be eligible to receive an
annual calendar year bonus based upon Employee’s and the Company’s achievement of certain individual and Company goals that will be set for Employee by the Board or its designee (the “Annual Bonus”). The amount of the target
Annual Bonus will be equal to thirty percent (30%) of Employee’s then-current Base Salary as of the date of the payment; provided that the actual amount of the Annual Bonus may be greater or less than such

	 	
target amount. One half of the Annual Bonus awarded for any given year will be paid in cash, and the other half of the Annual Bonus awarded for any given year will be paid, in the sole discretion
of the Company, either in cash or in the form of options to acquire shares of the Company’s common stock (or other equity interests as selected by the Company), in any case subject to the terms and conditions of the Company’s equity
compensation plan as in effect as of the date of such grant. For any grant of stock options or equity issued pursuant to this Section 3(b), the number of options or other equity interests allocated to the
non-cash portion of the Annual Bonus will be determined by the Company in its sole discretion. The Board or its designee will have the sole discretion to set the applicable individual and Company goals, to
determine whether the goals have been met, and to determine the amount of the Annual Bonus. The Annual Bonus for any given year will be paid between January 1 and January 31 in the year immediately following the year in which the Annual
Bonus, if any, is earned. Employee must be employed by the Company on December 31 of the bonus year in order to receive the Annual Bonus for that year. 

3. PROPER AMENDMENT. The parties expressly acknowledge and agree that this Amendment constitutes a proper amendment and modification of
the Employment Agreement by written agreement executed by the parties pursuant to Section 7 of the Employment Agreement. 
 4.
REMAINDER OF EMPLOYMENT AGREEMENT. Except as expressly set forth in this Amendment, the provisions of the Employment Agreement remain in full force and effect, in their entirety, in accordance with their terms. 

5. MISCELLANEOUS. This Amendment shall be governed, construed, and interpreted in accordance with the laws of the State of North
Carolina, without giving effect to conflicts of laws principles. The parties agree that this Amendment may only be modified in a signed writing executed by both parties. This Amendment shall be binding upon and shall inure to the benefit of the
parties hereto and their respective heirs, successors and assigns. This Amendment may be executed in separate counterparts, each of which is deemed to be an original and all of which taken together constitute one agreement. Facsimile or PDF
reproductions of original signatures will be deemed binding for the purpose of the execution of this Amendment. 
 [SIGNATURE PAGE FOLLOWS]

 IN WITNESS WHEREOF, the parties have executed this Amendment to Employment Agreement to be
effective as of the day and year first above written. 
  

									
	Company:
			
	G1 THERAPEUTICS, INC.	 		 	Employee:
					
	By:	 	 /s/ Mark A. Velleca
	 		 	By:	 	 /s/ Jennifer Moses

		 	Mark A. Velleca	 		 		 	Jennifer Moses
		 	President and Chief Executive Officer	 		 		 	

 EMPLOYMENT AGREEMENT 

This EMPLOYMENT AGREEMENT (the “Agreement”), is made and entered into effective as of May 10, 2016 (the
“Effective Date”), by and between G1 Therapeutics, Inc., a Delaware corporation (the “Company”), and Jennifer Moses (“Employee”). 

1. EMPLOYMENT; DUTIES. The Company agrees to employ Employee as its Vice President of Finance and Administration, and Employee agrees
to accept such employment upon the terms and conditions hereinafter set forth. Employee will perform such services for the Company as are customarily associated with such position and as may otherwise be assigned to the Employee from time to time by
the Company’s Chief Executive Officer or his designee. Employee will devote Employee’s full business time and attention to the business and affairs of the Company, and will perform Employee’s duties diligently and to the best of
Employee’s ability, in compliance with the Company’s policies and procedures and the laws and regulations that apply to the Company’s business. 

2. TERM; TERMINATION. Employee’s employment under this Agreement will commence as of the Effective Date and will continue until
terminated by either party. Employee’s employment with the Company is at-will, and either party can terminate the employment relationship and/or this Agreement at any time, for any or no cause or reason,
and with or without prior notice, subject to the applicable terms of Section 4. Upon termination of Employee’s employment by either party for any reason, Employee will resign Employee’s position(s), if any, as an officer or director
of the Company, as a member of the Company’s Board of Directors (the “Board”) and any Board committees, as well as any other positions Employee may hold with or for the benefit of the Company and/or its affiliates. 

3. COMPENSATION. As compensation for the services to be rendered by Employee under this Agreement, the Company will provide the
following compensation and benefits during Employee’s employment hereunder. 
 (a) BASE SALARY. The Company will pay Employee a
base salary (the “Base Salary”) at an annual rate of One Hundred and Eighty-Five Thousand Three Hundred Dollars ($185,300), payable in equal installments in accordance with the Company’s customary payroll practices as in effect
from time to time. The Base Salary may be reviewed from time to time by the Company and may be increased in the sole discretion of the Company. The Base Salary may also be decreased in connection with any Company-wide decrease in executive
compensation. 
 (b) ANNUAL BONUS. Employee will be eligible to receive an annual calendar year bonus based upon Employee’s and
the Company’s achievement of certain individual and Company goals that will be set for Employee by the Board or its designee (the “Annual Bonus”). The amount of the target Annual Bonus will be equal to twenty percent (20%) of
Employee’s then-current Base Salary as of the date of the payment; provided that the actual amount of the Annual Bonus may be greater or less than such target amount. One half of the Annual Bonus awarded for any given year will be paid
in cash, and the other half of the Annual Bonus awarded for any given year will be paid, in the sole discretion of the Company, either in cash or in the form of options to acquire shares of the Company’s common stock (or other equity interests
as selected by the Company), in any case subject to the terms and conditions of the Company’s equity compensation 

 
plan as in effect as of the date of such grant. For any grant of stock options or equity issued pursuant to this Section 3(b), the number of options or other equity interests allocated to the non-cash portion of the Annual Bonus will be determined by the Company in its sole discretion. The Board or its designee will have the sole discretion to set the applicable individual and Company goals, to determine
whether the goals have been met, and to determine the amount of the Annual Bonus. The Annual Bonus for any given year will be paid between January 1 and January 31 in the year immediately following the year in which the Annual Bonus, if
any, is earned. Employee must be employed by the Company on December 31 of the bonus year in order to receive the Annual Bonus for that year. 

(c) STOCK OPTIONS. Subject to approval by the Board on May 10, 2016, Employee will be (or has been) granted stock options to
purchase 180,000 shares of the Company’s common stock (the “Options”) at a per share exercise price equal to the Fair Market Value (as defined in the 2011 Equity Incentive Plan) of the Company’s common stock on the date of
grant. The Options will be, to the maximum extent permissible, treated as “incentive stock options” within the meaning of Section 422 of the Internal Revenue Code and the rules and regulations thereunder. The Options will be granted
pursuant to and subject to the terms and conditions of the Company’s 2011 Equity Incentive Plan and will be further subject to the terms of a stock option agreement as approved by the Board setting forth the exercise price, vesting conditions
and other restrictions. One fourth of the total number of such Options will vest on the first anniversary of the date hereof, and one forty eighth (1/48th) of the total number of Options will vest each month over the following thirty six
(36) months thereafter, so long as Employee remains employed by the Company through each such vesting date. Fifty Percent (50%) of any unvested Options will vest immediately prior to, and subject to, the consummation of a Change in Control (as
defined below) and, subject to Employee’s execution of the release of claims described in Section 4(b), any remaining unvested Options will immediately vest if Employee’s employment is terminated by the Company without Cause (as defined
below) or Employee resigns with Good Reason (as defined below) within ninety (90) days following a Change in Control. A “Change in Control” means (i) the Company’s merger or consolidation with or into another entity
such that the stockholders of the Company prior to such transaction do not or are not expected to own a majority of the voting stock of the surviving entity, (ii) the sale or other disposition of all or substantially all of the assets of the
Company, (iii) the sale or other disposition of greater than 50% of the then-outstanding voting stock of the Company by the holders thereof to one or more persons or entities who are not then stockholders of the Company. 

(d) VACATION. Employee will be eligible for paid vacation time off in accordance with, and subject to, the Company’s policies and
procedures in effect from time to time. 
 (e) BENEFITS. Employee will (subject to applicable eligibility requirements) receive such
other benefits as are provided from time to time to other similarly-situated employees of the Company pursuant to the Company’s policies and procedures as they may be instituted from time to time. All such benefits are subject to the provisions
of their respective plan documents in accordance with their terms. Employee acknowledges and agrees that the Company has the unilateral right to amend, modify or terminate its employee benefit plans or policies to the maximum extent allowed by law.

  
 2 

 (f) EXPENSE REIMBURSEMENT. The Company will reimburse Employee for all reasonable business
expenses incurred by Employee in connection with the performance of Employee’s duties hereunder, subject to Employee’s compliance with the Company’s reimbursement policies in effect from time to time. All reimbursements provided under
this Agreement will be made or provided in accordance with the requirements of Section 409A of the Internal Revenue Code and the rules and regulations thereunder including, where applicable, the requirement that (i) any reimbursement is for
expenses incurred during Employee’s lifetime (or during a shorter period of time specified in this Agreement); (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement
in any other calendar year; (iii) the reimbursement of an eligible expense shall be made no later than the last day of the calendar year following the year in which the expense is incurred; and (iv) the right to reimbursement or in kind
benefits is not subject to liquidation or exchange for another benefit. 
 (g) WITHHOLDINGS. The Company will withhold from any
amounts payable under this Agreement, such federal, state and local taxes, as the Company reasonably determines are required to be withheld pursuant to applicable law. 

4. EFFECT OF TERMINATION. 

(a) GENERALLY. When Employee’s employment with the Company is terminated for any reason, Employee, or Employee’s estate, as
the case may be, will be entitled to receive the compensation and benefits earned through the effective date of termination, along with reimbursement for any approved business expenses that Employee has timely submitted for reimbursement in
accordance with the Company’s expense reimbursement policy or practice. 
 (b) SEPARATION BENEFITS UPON CERTAIN TERMINATIONS. If
the Company terminates Employee’s employment without Cause (as defined below), or if Employee resigns Employee’s employment for Good Reason (as defined below), then conditioned upon Employee executing a Release (as defined below) following
such termination, Employee will be entitled to receive an amount equal to payment of Employee’s then-current Base Salary for a period of six (6) months (the “Separation Benefits”). The Separation Benefits are conditioned
upon Employee executing a release of claims in a form satisfactory to the Company (the “Release”) within the time specified therein, which Release is not revoked within any time period allowed for revocation under applicable law.
The Separation Benefits will be payable to Employee over time in accordance with the Company’s payroll practices and procedures beginning on the sixtieth (60th) day following the termination of Employee’s employment with the Company,
provided that the Company, in its sole discretion, may begin the payments earlier. For avoidance of doubt, the termination of Employee’s employment as a result of Employee’s death or disability (meaning the inability of Employee, due to
the condition of Employee’s physical, mental or emotional health, effectively to perform the essential functions of Employee’s job with or without reasonable accommodation for a continuous period of more than 90 days or for 90 days in any
period of 180 consecutive days, as determined by the Board in its sole discretion in consultation with a physician retained by the Company) will not constitute a termination without Cause triggering the rights described in this Section 4(b). 

  
 3 

 (c) CAUSE. For purposes of this Agreement, “Cause” means:
(i) Employee’s fraud, embezzlement or misappropriation with respect to the Company; (ii) Employee’s material breach of fiduciary duties to the Company; (iii) Employee’s willful or negligent misconduct;
(iv) Employee’s material breach of this Agreement; (v) Employee’s willful failure or refusal to perform Employee’s material duties under this Agreement or failure to follow any specific lawful instructions of the Company;
(vi) Employee’s conviction or plea of nolo contendere in respect of a felony or of a misdemeanor involving moral turpitude; (vii) Employee’s alcohol or substance abuse which has a material adverse effect on Employee’s
ability to perform Employee’s duties under this Agreement; or (viii) Employee’s engagement in a form of discrimination or harassment prohibited by law (including, without limitation, discrimination or harassment based on race, color,
religion, sex, national origin, age or disability). In the event that the Company concludes that Employee has engaged in acts constituting in Cause as defined in clause (iii), (iv), (v), or (vii) above, prior to terminating this Agreement for
Cause the Company will provide Employee with at least fifteen (15) days’ advance written notice of the specific circumstances constituting such Cause, and an opportunity to correct such circumstances. 

(d) GOOD REASON. In order for Employee to resign for Good Reason, Employee must provide written notice to the Company of the existence
of the Good Reason condition within thirty (30) days of the initial existence of such Good Reason condition. Upon receipt of such notice, the Company will have thirty (30) days during which it may remedy the Good Reason condition and not
be required to provide for the benefits described in Section 4(b) above as a result of such proposed resignation if successfully remedied. If the Good Reason condition is not remedied within such thirty (30) day period, Employee may resign
based on the Good Reason condition specified in the notice effective no later than thirty (30) days following the expiration of the thirty (30) day cure period. For purposes of this Agreement, “Good Reason” means the
occurrence of any of the following events without Employee’s consent: (i) a material reduction of Employee’s Base Salary not generally applicable to other executive-level employees of the Company, (ii) a material diminution of
the Employee’s authority, duties, or responsibilities, (iii) a relocation of Employee’s primary workplace to a location that is more than fifty (50) miles from the location of Employee’s primary workplace as of the date
hereof, or (iv) the Company’s material breach of this Agreement. 
 (e) APPLICATION OF INTERNAL REVENUE CODE SECTION
409A. Notwithstanding anything to the contrary set forth herein, any payments and benefits provided under this Section 4 that constitute “deferred compensation” within the meaning of Section 409A of the Internal Revenue
Code and the regulations and other guidance thereunder and any state law of similar effect (collectively “Section 409A”) will not commence in connection with Employee’s termination of employment unless and until Employee has also
incurred a “separation from service” (as such term is defined in Treasury Regulation Section 1.409A-1(h) (a “Separation From Service”), unless the Company reasonably determines that
such amounts may be provided to Employee without causing Employee to incur an additional tax under Section 409A. The parties intend that each installment of the Separation Benefits payments provided for in this Agreement is a separate
“payment” for purposes of Treasury Regulation Section 1.409A-2(b)(2)(i). For the avoidance of doubt, the parties intend that payments of the Separation Benefits set forth in this Agreement satisfy,
to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulation Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9). However, if the Company determines that the Separation Benefits constitute “deferred compensation” under Section 409A and Employee is, on the termination of service, a “specified

  
 4 

 
employee” of the Company or any successor entity thereto, as such term is defined in Section 409A, then, solely to the extent necessary to avoid the incurrence of the adverse personal tax
consequences under Section 409A, the timing of the Separation Benefits payments will be delayed until the earlier to occur of: (i) the date that is six months and one day after Employee’s Separation From Service, or (ii) the date of
Employee’s death (such applicable date, the “Specified Employee Initial Payment Date”), the Company (or the successor entity thereto, as applicable) will (A) pay to Employee a lump sum amount equal to the sum of the
Separation Benefits payments that Employee would otherwise have received through the Specified Employee Initial Payment Date if the commencement of the payment of the Separation Benefits had not been so delayed pursuant to this Section and
(B) commence paying the balance of the Separation Benefits in accordance with the applicable payment schedules set forth in this Agreement. 

(f) NO FURTHER OBLIGATIONS. Except as expressly provided above or as otherwise required by law, the Company will have no obligations to
Employee in the event of the termination of this Agreement for any reason. 
 5. EMPLOYEE REPRESENTATIONS. Employee represents and
warrants that Employee is not obligated or restricted under any agreement (including any non-competition or confidentiality agreement), judgment, decree, order or other restraint of any kind that could impair
Employee’s ability to perform the duties and obligations required of Employee hereunder. Employee further agrees that Employee will not divulge to the Company any confidential information and/or trade secrets belonging to others, including
Employee’s former employers, nor will the Company seek to elicit from Employee such information. Consistent with the foregoing, Employee will not provide to the Company, and the Company will not request, any documents or copies of documents
containing such information. 
 6. NOTICES. Any notice required to be given hereunder will be sufficient if in writing and hand
delivered or sent by mail, return receipt requested, postage prepaid, in the case of Employee, to Employee’s address shown on the Company’s records, and in the case of the Company, to 79 T.W. Alexander Drive, 4401 Research Commons, Suite
105, Research Triangle Park, NC 27709, or to such other addresses as either party shall specify to the other. 
 7. AMENDMENT;
WAIVER. No amendment of any provision of this Agreement will be valid unless the amendment is in writing and signed by the Company and Employee. No waiver of any provision of this Agreement will be valid unless the waiver is in writing and
signed by the waiving party. The failure of a party at any time to require performance of any provision of this Agreement will not affect such party’s rights at a later time to enforce such provision. No waiver by a party of any breach of this
Agreement will be deemed to extend to any other breach hereunder or affect in any way any rights arising by virtue of any other breach. 

8. GOVERNING LAW; VENUE. This Agreement will be governed by and construed in accordance with the laws of the State of North Carolina,
without regard to that body of law known as choice of law. The parties agree that any litigation arising out of or related to this Agreement or Employee’s employment by the Company will be brought exclusively in any state or federal court in
Durham County, North Carolina. Each party (i) consents to the personal jurisdiction of said courts, (ii) waives any venue or inconvenient forum defense to any proceeding maintained in such courts, and (iii) agrees not to bring any
proceeding arising out of or relating to this Agreement or Employee’s employment by the Company in any other court. 

  
 5 

 9. BENEFIT. This Agreement will be binding upon and will inure to the benefit of each of
the parties hereto, and to their respective heirs, representatives, successors and permitted assigns. Employee may not assign any of Employee’s rights or delegate any of Employee’s duties under this Agreement. 

10. ENTIRE AGREEMENT; OTHER AGREEMENTS. This Agreement contains the entire agreement and understanding by and between the Company and
Employee with respect to the subject matter hereof, and any representations, promises, agreements or understandings, written or oral, not herein contained will be of no force or effect; provided, however, that Employee is also subject to the terms
and conditions of (i) that certain Employee Non-Competition and Non-Solicitation Agreement, dated April 15, 2016, by and between Employee and the Company, and
(ii) that certain Employee Confidentiality and Inventions Agreement, dated February 19, 2015, by and between Employee and the Company, each of which remains in full force and effect. 

11. CAPTIONS; RULE OF CONSTRUCTION. The captions in this Agreement are for convenience only and in no way define, bind or describe the
scope or intent of this Agreement. The terms and provisions of this Agreement will not be construed against the drafter or drafters hereof All parties hereto agree that the language of this Agreement will be construed as a whole according to its
fair meaning and not strictly for or against any of the parties hereto. 
 12. COUNTERPARTS. This Agreement may be executed in one or
more counterparts, each of which will be deemed an original but all of which together will constitute one and the same agreement. Facsimile or PDF reproductions of original signatures will be deemed binding for the purpose of the execution of this
Agreement. 
 13. SEVERABILITY. Each provision of this Agreement is severable from every other provision of this Agreement. Any
provision of this Agreement that is determined by any court of competent jurisdiction to be invalid or unenforceable will not affect the validity or enforceability of any other provision. Any provision of this Agreement held invalid or unenforceable
only in part or degree will remain in full force and effect to the extent not held invalid or unenforceable. 
 14. SURVIVAL. The
terms of Sections 4 through 14 will survive the termination or expiration of this Agreement for any reason. 
 [Signature Page Follows.]

  
 6 

 IN WITNESS WHEREOF, the parties have executed this Agreement effective as of the Effective Date.

  

			
	G1 THERAPEUTICS, INC.
		
	By:	 	 /s/ Mark Velleca

	Name:	 	Mark Velleca
	Title:	 	CEO
	
	EMPLOYEE:
	
	 /s/ Jennifer Moses

	Jennifer Moses

  
 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00270-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00270-of-00352.parquet"}]]